248 related articles for article (PubMed ID: 31856946)
1. Predictors of initiation of and retention on medications for alcohol use disorder among people living with and without HIV.
Oldfield BJ; McGinnis KA; Edelman EJ; Williams EC; Gordon AJ; Akgün K; Crystal S; Fiellin LE; Gaither JR; Goulet JL; Korthuis PT; Marshall BDL; Justice AC; Bryant K; Fiellin DA; Kraemer KL
J Subst Abuse Treat; 2020 Feb; 109():14-22. PubMed ID: 31856946
[TBL] [Abstract][Full Text] [Related]
2. Impact of behavioral and medication treatment for alcohol use disorder on changes in HIV-related outcomes among patients with HIV: A longitudinal analysis.
McGinnis KA; Skanderson M; Edelman EJ; Gordon AJ; Korthuis PT; Oldfield B; Williams EC; Wyse J; Bryant K; Fiellin DA; Justice AC; Kraemer KL
Drug Alcohol Depend; 2020 Dec; 217():108272. PubMed ID: 32971391
[TBL] [Abstract][Full Text] [Related]
3. Real-world effectiveness of pharmacological treatments of alcohol use disorders in a Swedish nation-wide cohort of 125 556 patients.
Heikkinen M; Taipale H; Tanskanen A; Mittendorfer-Rutz E; Lähteenvuo M; Tiihonen J
Addiction; 2021 Aug; 116(8):1990-1998. PubMed ID: 33394527
[TBL] [Abstract][Full Text] [Related]
4. Using a cascade of care framework to identify gaps in access to medications for alcohol use disorder in British Columbia, Canada.
Socias ME; Scheuermeyer FX; Cui Z; Mok WY; Crabtree A; Fairbairn N; Nolan S; Slaunwhite A; Ti L
Addiction; 2023 Nov; 118(11):2128-2138. PubMed ID: 37488683
[TBL] [Abstract][Full Text] [Related]
5. Differences in Receipt of Alcohol-Related Care Across Rurality Among VA Patients Living With HIV With Unhealthy Alcohol Use.
Bensley KM; Fortney J; Chan G; Dombrowski JC; Ornelas I; Rubinsky AD; Lapham GT; Glass JE; Williams EC
J Rural Health; 2019 Jun; 35(3):341-353. PubMed ID: 30703856
[TBL] [Abstract][Full Text] [Related]
6. Medication prescribing for alcohol use disorders during alcohol-related encounters in a Colorado regional healthcare system.
Chockalingam L; Burnham EL; Jolley SE
Alcohol Clin Exp Res; 2022 Jun; 46(6):1094-1102. PubMed ID: 35723682
[TBL] [Abstract][Full Text] [Related]
7. Pharmacotherapy for alcohol use disorder among adults with medical disorders in Sweden.
Månsson A; Danielsson AK; Sjöqvist H; Glatz T; Lundin A; Wallhed Finn S
Addict Sci Clin Pract; 2024 May; 19(1):41. PubMed ID: 38764075
[TBL] [Abstract][Full Text] [Related]
8. Strategies to increase implementation of pharmacotherapy for alcohol use disorders: a structured review of care delivery and implementation interventions.
Williams EC; Matson TE; Harris AHS
Addict Sci Clin Pract; 2019 Feb; 14(1):6. PubMed ID: 30744686
[TBL] [Abstract][Full Text] [Related]
9. Medications for alcohol use disorder improve survival in patients with hazardous drinking and alcohol-associated cirrhosis.
Rabiee A; Mahmud N; Falker C; Garcia-Tsao G; Taddei T; Kaplan DE
Hepatol Commun; 2023 Apr; 7(4):. PubMed ID: 36972386
[TBL] [Abstract][Full Text] [Related]
10. Trends in the Use of Naltrexone for Addiction Treatment among Alcohol Use Disorder Admissions in U.S. Substance Use Treatment Facilities.
Qeadan F; Mensah NA; Gu LY; Madden EF; Venner KL; English K
Int J Environ Res Public Health; 2021 Aug; 18(16):. PubMed ID: 34444639
[TBL] [Abstract][Full Text] [Related]
11. SAEM GRACE: Anti-craving medications for alcohol use disorder treatment in the emergency department: A systematic review of direct evidence.
Punia K; Scott W; Manuja K; Sabbineni M; Campbell K; Balodis IM; MacKillop J
Acad Emerg Med; 2024 May; 31(5):504-514. PubMed ID: 37735346
[TBL] [Abstract][Full Text] [Related]
12. Rates of prescription orders for United States active duty service members diagnosed with alcohol use disorder.
Peters ZJ; Kincaid MW; Greenberg JG; Quah RF; Curry JC
Subst Abus; 2021; 42(4):638-645. PubMed ID: 32870103
[No Abstract] [Full Text] [Related]
13. Adherence Across FDA-Approved Medications for Alcohol Use Disorder in a Veterans Administration Population.
Walker JR; Korte JE; McRae-Clark AL; Hartwell KJ
J Stud Alcohol Drugs; 2019 Sep; 80(5):572-577. PubMed ID: 31603760
[TBL] [Abstract][Full Text] [Related]
14. Impact of policy changes and drug shortages on acamprosate and naltrexone use in Ontario, Canada.
Konstantelos N; Tourchian N; McCormack D; Lecce P; Tadrous M; Gomes T
Drug Alcohol Depend; 2023 Jan; 242():109705. PubMed ID: 36463765
[TBL] [Abstract][Full Text] [Related]
15. Very Low Frequency of Drug Therapy of Alcohol Dependence in Germany - Analysis of Data of A Statutory Health Insurance.
Scherbaum N; Holzbach R; Stammen G; Kirchof U; Bonnet U
Pharmacopsychiatry; 2020 Jan; 53(1):37-39. PubMed ID: 31132796
[TBL] [Abstract][Full Text] [Related]
16. Outcomes After Initiation of Medications for Alcohol Use Disorder at Hospital Discharge.
Bernstein EY; Baggett TP; Trivedi S; Herzig SJ; Anderson TS
JAMA Netw Open; 2024 Mar; 7(3):e243387. PubMed ID: 38551564
[TBL] [Abstract][Full Text] [Related]
17. Multiple Psychiatric Morbidity and Continued Use of Naltrexone for Alcohol Use Disorder.
Muvvala SB; O'Malley SS; Rosenheck R
Am J Addict; 2021 Jan; 30(1):55-64. PubMed ID: 32805083
[TBL] [Abstract][Full Text] [Related]
18. Advances in Pharmacotherapy Development: Human Clinical Studies.
Litten RZ; Falk DE; Ryan ML; Fertig J; Leggio L
Handb Exp Pharmacol; 2018; 248():579-613. PubMed ID: 29294197
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Alcohol Use Disorder.
Patel AK; Balasanova AA
JAMA; 2021 Feb; 325(6):596. PubMed ID: 33560323
[No Abstract] [Full Text] [Related]
20. Review of Evidence-Based Strategies to Treat Alcohol Use Disorder.
Worley J
J Psychosoc Nurs Ment Health Serv; 2021 Dec; 59(12):7-11. PubMed ID: 34846245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
